Replies to post #93365 on Biotech Values

[DewDiligence]

Closing of the donut hole could conceivably prove to be a net positive for Big Pharma if it can significantly increase medication compliance for patients with such “asymptomatic” chronic conditions as hypertension and dyslipidemia. The article in #msg-48270329 speaks to this point.

[DewDiligence]

Things could have been much worse [for Big Pharma] as the legislation removes the concern that was overhanging the industry on matters that could have devastated pharma, such as government price controls and/or importation.

I wholeheartedly agree with respect to the new law’s lack of government price controls. However, re-importing prescription drugs on a large scale would be utterly unworkable, and hence I’ve never considered re-importation to be anything but a bluff and a campaign issue.